PharmaMar

Spanish pharmaceutical company

BME Madrid ISIN ES0169501022 LEI 959800QWKZ45ZQC2AV58
Follow PharmaMar Weekly email: filings, results

Financials

Reported figures only · latest: fiscal 2025 EUR · IFRS
Revenue, last year €221.4M +26.6% vs prior year
Net income €75M +187% vs prior year
EPS, diluted €4.30 +188.6% vs prior year
Operating cash flow €53.1M +781.5% vs prior year
Revenue by fiscal year
€270M
€229.8M
€196.3M
€158.2M
€174.9M
€221.4M
FY20 FY21 FY22 FY23 FY24 FY25

Source: ESEF annual reports · latest filing

The long view

Fiscal years as reported · ESEF annual reports, IFRS
Revenue and net income7 fiscal years
  • Revenue
  • Net income
−€100M€0€100M€200M€300MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25€221.4M€75M
FY24€174.9M€26.1M
FY23€158.2M€1.1M
FY22€196.3M€49.4M
FY21€229.8M€92.9M
FY20€270M€137.3M
FY19€85.8M−€11.4M
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−50%0%50%100%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2594.5%27.4%33.9%
FY2495.3%3.7%14.9%
FY2393.9%−2.4%0.7%
FY2293.1%22.4%25.1%
FY2192.8%40.2%40.4%
FY2094.9%57.8%50.8%
FY1993.9%−20.4%−13.3%
Returned to shareholdersDividends paid and shares bought back
  • Dividends
  • Buybacks
€0€20M€40M€60M€80MFY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearDividendsBuybacks
FY25€13.9M€34.1M
FY24€11.4M€18.6M
FY23€11.7M€37.9M
FY22€11.8M€50.2M
FY21€10.9M€40.7M
FY20€8.8M€63.7M
FY19€0€7.5M
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • PharmaMar
  • Healthcare median
−100%−50%0%50%100%FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearPharmaMarHealthcare median
FY2533.9%−30.6%
FY2414.9%−47%
FY230.7%−58%
FY2225.1%−80.4%
FY2140.4%−71.9%
FY2050.8%−62.2%
FY19−13.3%−46.3%